Sunshine Heart Inc (NASDAQ:CHFS) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $15.00 for the company, according to Zacks. Zacks has also given Sunshine Heart an industry rank of 186 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Wednesday, December 6th.
TRADEMARK VIOLATION WARNING: “Analysts Set $15.00 Target Price for Sunshine Heart Inc (CHFS)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/13/analysts-set-15-00-target-price-for-sunshine-heart-inc-chfs.html.
About Sunshine Heart
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.